Aclaris Therapeutics (ACRS) Total Current Liabilities (2017 - 2025)
Historic Total Current Liabilities for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to $25.6 million.
- Aclaris Therapeutics' Total Current Liabilities rose 3621.92% to $25.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.6 million, marking a year-over-year increase of 3621.92%. This contributed to the annual value of $31.6 million for FY2024, which is 208.06% up from last year.
- Per Aclaris Therapeutics' latest filing, its Total Current Liabilities stood at $25.6 million for Q3 2025, which was up 3621.92% from $26.8 million recorded in Q2 2025.
- Over the past 5 years, Aclaris Therapeutics' Total Current Liabilities peaked at $31.6 million during Q4 2024, and registered a low of $14.5 million during Q1 2021.
- In the last 5 years, Aclaris Therapeutics' Total Current Liabilities had a median value of $20.1 million in 2024 and averaged $21.3 million.
- Per our database at Business Quant, Aclaris Therapeutics' Total Current Liabilities plummeted by 3130.67% in 2024 and then surged by 7114.53% in 2025.
- Over the past 5 years, Aclaris Therapeutics' Total Current Liabilities (Quarter) stood at $22.9 million in 2021, then decreased by 4.33% to $21.9 million in 2022, then skyrocketed by 41.09% to $31.0 million in 2023, then rose by 2.08% to $31.6 million in 2024, then dropped by 18.88% to $25.6 million in 2025.
- Its last three reported values are $25.6 million in Q3 2025, $26.8 million for Q2 2025, and $21.5 million during Q1 2025.